Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial Meeting Abstract
| Authors: | Stilgenbauer, S.; Hallek, M. J.; Coutre, S. E.; Furman, R. R.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; Ghia, P.; Coiffier, B.; O'Brien, S. M.; Tausch, E.; Sharman, J. P.; Ruppert, S.; Schuster, A.; Kronig, H. |
| Abstract Title: | Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 37 |
| Issue: | Suppl.5 |
| Meeting Dates: | 2014 Oct 10-14 |
| Meeting Location: | Hamburg, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2014-10-01 |
| Start Page: | 184 |
| Language: | English |
| ACCESSION: | WOS:000343816900446 |
| PROVIDER: | wos |
| PUBMED: | 25301272 |
| DOI: | 10.1159/000368945 |
| Notes: | Meeting Abstract: V570 -- Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Medical Oncology -- 5 -- Source: Wos |
